Please login to the form below

Not currently logged in
Email:
Password:

Advaxis

This page shows the latest Advaxis news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Immunotherapy firm Advaxis cuts back, Pfizer wins price gouging appeal

Daily Brief: Immunotherapy firm Advaxis cuts back, Pfizer wins price gouging appeal

BIOTECH. Immunotherapy-focused Advaxis forced to scale back. Billions of dollars of investment is flooding into immunotherapy-based R&D, but some overstretched biotechs are having to scale back on ambitious ... goals. Once such company is Advaxis, which

Latest news

More from news
Approximately 5 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Acquisition - company. 705. Advaxis/ SELLAS Life Sciences Group. Advaxis' Lm-based antigen delivery technology with SELLAS’WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S) (pre-clinical).

  • Deal Watch August 2016 Deal Watch August 2016

    624. Advaxis (US). Amgen (US). Licence. ADXS-NEO, preclinical investigational cancer immunotherapy treatment.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics